Compare BridgeBio Pharma Inc (BBIO) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs iShares MSCI United Kingdom (FTSE) — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while iShares MSCI United Kingdom (FTSE) trades at $48.28. Which is the better fit depends on your goals.
| BBIO | EWU | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.17 | $48.68 |
52-Week Low | $47.29 | $40.90 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
EWU, the iShares MSCI United Kingdom ETF, trades at $48.64, up 0.7% with strong bullish technical signals from moving averages. The ETF shows mixed institutional activity with recent purchases by Balefire LLC and Fifth Third Bancorp offset by Bank of America trimming its position. UK market sentiment remains influenced by Middle East tensions, oil price volatility, and new political leadership under Prime Minister Andy Burnham.
The ETF's outlook balances UK economic resilience against geopolitical risks. Investment opportunity lies in exposure to FTSE 100 companies amid potential economic stabilization, while risks include ongoing Middle East tensions affecting energy markets and uncertainty around new UK fiscal policies under the Burnham administration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →
